Skip to content

We believe in clinical trials enriched with responders to treatment – accelerating approvals of life-changing therapies

Unlock the power of mechanistic biomarkers to maximize probability of trial success

We go beyond conventional biomarker discovery to deliver mechanistically driven clinical biomarkers that map drug candidates to the underlying biology of patients in the trial's primary indication.

Using our platform, we stratify patient populations to identify subgroups based on shared disease mechanisms. This enables biomarker-guided development strategies that enrich trials with responsive participants to eliminate risk and maximize the probability of success across all disease areas.

This is precision drug development.

2.6x greater

probability of trial success for drugs with genetic support. 

We go much further.

Succeed where others fail-min

Succeed where others would fail

Our unique understanding of in which patients a drug candidate will be effective is key to the success of clinical programs.

We identify the causal biology of disease and find biomarkers that reflect the mechanisms responsible for disease progression and treatment response in well-defined patient subgroups.


 

Patient stratification biomarkers to identify and recruit responsive subpopulations.

Predictive biomarkers to distinguish the biology underpinning responders from non-responders before or early in treatment.

Mechanistic biomarkers that align with drug MoA to support regulatory submissions and development of companion diagnostics.

Find and recruit super responders

We identify and enable enrollment of the most scientifically robust and commercially attractive patient populations.

In clinical development, we enable our partners to:

  Stratify and understand the mechanisms driving disease
  Discover biomarkers associated with drug response
  Enhance statistical power and detect efficacy signals earlier
  Develop complementary diagnostics to identify responders
  Succeed with smaller trials that are faster to readout

Our biomarker-led development strategies de-risk clinical programs, improve regulatory confidence and maximize value.


Maximize probability of success in clinical trials

Mechanistic patient stratification of Alzheimer's disease
Our analysis found that only 32% of Alzheimer’s patients in a trial would  respond to drugs targeting amyloid – not enough to achieve efficacy endpoints – highlighting the need to enrich trials with patients who will respond to treatments targeting a specific mechanism.

 

Our pathway to success

Biology

We produce unrivaled insights into causal biology and highlight which mechanisms are relevant to which patients, reproducibly, across multiple ancestries.

Biomarkers

We find mechanism- and drug response-based biomarkers to identify responders and support selected targets through development.

Efficacy

Our biomarkers inform trial design, predict efficacy, and enrich patient cohorts to maximize the likelihood of achieving efficacy endpoints in trials. 

Diagnostics

These biomarkers are reduced to clinical practice in the form of low-cost genotypic tests, supporting product launch and enhancing market adoption.

Use cases

We map drug candidates to patient responders with mechanistic biomarkers that inform inclusion criteria, rescue unsuccessful trials, and de-risk each phase of clinical development.

Design

Precision trial design

Our mechanism-based patient stratification biomarkers inform inclusion criteria for the design of mechanistically targeted clinical trials. 

These biomarkers identify the broadest set of patients most likely to benefit from a drug candidate and are used as a simple genotypic inclusion test to recruit patients - maximizing the likelihood of positive readouts.

Rescue

Efficacy trial rescue

We analyze drug response data from trials that missed efficacy endpoints, to find drug response biomarkers associated with strong responders. 

This allows the option to redesign a subsequent trial and reposition the therapy as a precision medicine for that subgroup of patients using the patient stratification biomarkers as a complementary diagnostic tool.

Indication

Indication selection

Is there another indication in which your asset might be more successful? 

We scan over 60 common diseases and their endotypes for causal links of a target’s mechanism of action to clinically relevant patient subgroups, finding the best candidate-indication pairing based on the prevalence of a chosen target’s mechanism in primary and/or secondary indications.

"Our clinical trials with PrecisionLife accelerate care for patients with some of the most debilitating, currently intractable diseases."

Rohit Gupta
Chief Executive Officer
Chronicle Bio

 

Let's talk

Patients are counting on us

We work with clinical development teams in biotech, pharma, and CROs to integrate mechanistic biomarkers into clinical programs across complex indications.

Contact us to explore how we can accelerate your development programs and increase your probability of success.